Ethics approval. The following arrangements have been made with regard to Ethic approvals: [insert from proposal template]
Ethics approval. 4.6.1 Spain (Aragon) Aragon Research Ethics Committees (CEICA). Decree 96/2013
4.6.2 Italy (Friuli Venezia Giulia)
Ethics approval. Institution and Investigator will not initiate the Study or enroll any subject until after the competent authority and the relevant EC/IRB has approved the Protocol, Informed Consent Form (“ICF”), subject recruitment materials, as applicable, and Xxxxxxxx has received a written copy of such approval. Any alterations of, or amendments to the Protocol must be approved by Institution, Investigator, EC/IRB and Sponsor prior to such alteration or amendment becoming effective. Neither the Institution nor the Investigator shall implement any Protocol amendment until it is approved by the relevant authorities and the EC/IRB.
Ethics approval. If yes, will the organization provide one? If yes, will the student need to do anything? Identify any privacy issues associated with field placement and products. Xxxxxxx who owns the research and how potential publication will be handled. Identify any health and safety concerns (e.x., students will be placed in environments with potential increased risk of injury or insecurity, potential contact with blood or other bodily fluids etc.) If yes, how much (Hourly? Stipend)? Other benefits, accommodations etc.
Ethics approval. In general, in order to respect at the highest possible level the care recipients enrolled in the Project, it is recommended that all sites look for an approval of the operational protocol by the local Ethical Committee. This seems particularly advisable to have a third party opinion on both the informed consent forms which will be submitted to all candidates, and on the general procedures of subsequent enrolment and follow-up. This is established even if no randomisation is employed and all enrolled subjects experience “non-usual integrated care”.
Ethics approval. It is the investigator’s responsibility to ensure that this protocol is reviewed and approved by the appropriate local IEC or IRB. A non-local IEC or IRB may be used if a local one is not available. The IEC or IRB must also review and approve the site’s informed consent form (ICF) and any other written information provided to the subject prior to any enrolment of subjects, and any advertisement that will be used for subject recruitment. The investigator or his/her designee must forward to GW copies of the IEC or IRB approval and the approved informed consent materials, which must be received by GW prior to the start of the study. If, during the study, it is necessary to amend either the protocol or the informed consent form, the investigator will be responsible for ensuring the IEC or IRB reviews and approves these amended documents. IEC or IRB approval of the amended ICF must be obtained before new subjects consent to take part in the study using this version of the form. Copies of the IEC or IRB approval of the amended ICF and the approved amended ICF must be forwarded to GW as soon as available.
Ethics approval. The Institution acknowledges that the supply of the Original Materials to the Recipient is conditional upon the Institution obtaining approval for the use of the Materials in the Project from an appropriately constituted research ethics committee. The Institution will provide the Supplier with a copy of such approval prior to the Supplier making the Original Materials available to the Recipient. The Institution confirms that the potential benefits of the Project outweigh any potential risk to the Donor(s).
Ethics approval. The Parties acknowledge that the Project may require approval by an institutional ethics and/or biosafety committees (or similar) of UNSW or the Participating Institutions. The relevant Party must use reasonable endeavours to promptly obtain that approval. Before such approvals are obtained, the Parties are not required to commence the Project.
Ethics approval. The study has been approved both in France (IARC ethics committee, IEC) and Tanzania. The IEC requested that in the instance of an oesophageal cancer patient being diagnosed under age 18, they should NOT be recruited to the study. This is reflected in the eligibility criteria for cases. Accordingly, NO minors below the age of 18 years should be invited as controls. The Tanzania approval was granted under KCRI PI Prof. Xxxxxx and we are in the process of updating the Xx Xxxx Xxxxxxxxxx.
Ethics approval we admit that:
a) This manuscript has not been submitted for publication anywhere, completely or in part, and it will not be submitted until a decision has been made by “peer to peer networking and applications”.
b) This manuscript presents original material which has not been previously published, completely or in part, in another journal.
